ERBB2 and breast carcinoma: Patients with HER2-positive breast cancer should be prioritized for receiving single chemo-drugs combined with dual blockade, while according to the APT trial, patients with tumors smaller than 2 cm and who are node-negative should be given paclitaxel combined with trastuzumab 25,26.